E Murat Tuzcu, MD
March 31st, 2014
Are We Equipped to Make a CHOICE Between TAVR Devices?
E Murat Tuzcu, MD
E. Murat Tuzcu offers his perspective on the CHOICE trial comparing the CoreValve and Edwards Sapien XT devices for transcatheter aortic valve replacement.
September 23rd, 2010
Howdy, PARTNER!
Michael Mack, M.D., E Murat Tuzcu, MD, L. David Hillis, MD and Richard A. Lange, MD, MBA
CardioExchange welcomes Mike Mack and E. Murat Tuzcu, investigators for the PARTNER trial, an ongoing, randomized study of transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis at high surgical risk. The first reported findings, published in the New England Journal of Medicine, showed an impressive 20% absolute reduction in 12-month mortality with […]
NEJM Journal Watch — Recent Cardiology Articles- More Data on Finerenone for Heart Failure with Preserved or Mildly Reduced Ejection Fraction
- Cardiovascular Outcomes of Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long Is Long Enough?